Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewsWire • 04/19/24
Zealand Pharma launches long-term incentive programs for Zealand's Board of Directors, Corporate Management and employees for 2024GlobeNewsWire • 04/19/24
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee WarrantsGlobeNewsWire • 03/26/24
Zealand Pharma to Participate in TD Cowen's 44th Annual Health Care ConferenceGlobeNewsWire • 03/01/24
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosisGlobeNewsWire • 02/26/24
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial resultsGlobeNewsWire • 02/20/24
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billionGlobeNewsWire • 01/08/24
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4thGlobeNewsWire • 01/02/24
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facilityGlobeNewsWire • 12/23/23
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndromeGlobeNewsWire • 12/22/23
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment BankGlobeNewsWire • 12/22/23
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observersGlobeNewsWire • 11/30/23